$-0.21 EPS Expected for Heat Biologics, Inc. (HTBX)

July 14, 2018 - By Alfred Lee

Analysts expect Heat Biologics, Inc. (NASDAQ:HTBX) to report $-0.21 EPS on August, 13.They anticipate $0.69 EPS change or 76.67 % from last quarter’s $-0.9 EPS. After having $-0.75 EPS previously, Heat Biologics, Inc.’s analysts see -72.00 % EPS growth. The stock decreased 1.72% or $0.04 during the last trading session, reaching $2.29. About 342,121 shares traded. Heat Biologics, Inc. (NASDAQ:HTBX) has declined 68.71% since July 14, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $47.65 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

More recent Heat Biologics, Inc. (NASDAQ:HTBX) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on July 09, 2018. Also Benzinga.com published the news titled: “20 Stocks Moving In Monday’s Pre-Market Session” on July 09, 2018. Streetinsider.com‘s news article titled: “HC Wainwright Starts Heat Biologics (HTBX) at Buy” with publication date: June 26, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: